We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Real world, open label experience with lacosamide against acute painful oxaliplatin‐induced peripheral neurotoxicity.
- Authors
Argyriou, Andreas A.; Kalofonou, Foteini; Litsardopoulos, Pantelis; Anastopoulou, Garifallia G.; Psimaras, Dimitri; Bruna, Jordi; Kalofonos, Haralabos P.
- Abstract
We report the outcome of a pilot, open‐label study that tested the potential of lacosamide (200 mg/bi.d) as an effective and safe symptomatic treatment against acute painful oxaliplatin‐induced peripheral neurotoxicity (OXAIPN). Lacosamide was introduced in 18 colorectal cancer patients with evidence of clinically significant acute, painful OXAIPN after infusion of the third course (T1) of oxaliplatin‐based chemotherapy (FOLFOX4) and was maintained until completion of all 12 courses (T4). The OXA‐Neuropathy Questionnaire (OXA‐NQ) was used to record the severity of acute OXAIPN; the PI‐NRS estimated the severity of neuropathic pain, while the chronic OXAIPN was graded with TNSc. The EuroQOL (EQ‐5D) instrument was also applied. The Patient Global Impression of Change (PGIC) scale measured the lacosamide‐attributed perception of change. LCM‐responders were considered those with ≥50% reduction in PI‐NRS and OXA‐NQ scores at T4, compared to T1. Patients experienced on T1 a median number of acute OXAIPN symptoms of 4 and had a median neuropathic pain severity score of 6, which was strongly related to lower quality of life, according to EQ‐VAS (P <.001). At T4, 12 patients (66.7%) were classified as responders. A significant clinical improvement was documented in the severity of acute OXAIPN and neuropathic pain in relation to lacosamide (P <.001) at T4 compared to T1, which was associated with improved EQ‐VAS scores (P <.001). Twelve patients scored PGIC ≥5 (lacosamide‐attributed) at T4. There were no incidences of early drop‐outs for safety reasons. Lacosamide appears to be an effective and well‐tolerated symptomatic treatment against acute, painful OXAIPN.
- Subjects
AMIDES; ATTITUDE (Psychology); CHANGE; CLINICAL trials; COLON tumors; PERIPHERAL neuropathy; NEURALGIA; QUALITY of life; RECTUM tumors; PILOT projects; PAIN measurement; OXALIPLATIN; VISUAL analog scale; TREATMENT effectiveness; SEVERITY of illness index
- Publication
Journal of the Peripheral Nervous System, 2020, Vol 25, Issue 2, p178
- ISSN
1085-9489
- Publication type
Article
- DOI
10.1111/jns.12374